Merck to Present Data on Rebif® (interferon beta-1a) and Cladribine Tablets for Multiple Sclerosis at 2nd Congress of the European Academy of Neurology

Darmstadt, Germany (ots/PRNewswire) -

Merck, a leading science and technology company, today announced
that clinical data on Rebif® (interferon beta-1a), the company's
high-dose, high-frequency interferon beta for relapsing forms of
multiple sclerosis, and Cladribine Tablets, an investigational, oral,
small molecule for the treatment of relapsing-remitting multiple
sclerosis (RRMS), will be presented at the 2nd Congress of the
European Academy of Neurology (EAN), taking place May 28-31, 2016, in
Copenhagen, Denmark.

(Logo: http://photos.prnewswire.com/prnh/20151019/278051LOGO )

(Logo: http://photos.prnewswire.com/prnh/20160524/371574LOGO )

For Rebif®, interim results from two non-interventional studies of
adherence patterns in patients with RRMS using the RebiSmart® device
and the RebiSTAR® patient service program will be presented.
Long-term clinical and radiological data from a retrospective,
observational study of patients with RRMS in Spain who were treated
with Rebif® for more than 10 years will also be presented. Finally, a
presentation will take place of a retrospective analysis of
real-world data describing factors for Rebif® discontinuation over
time among patients with RRMS.

For Cladribine Tablets, a re-analysis exploring the effect of
Cladribine Tablets in patients who would now be classified as having
early MS will be presented. Also, results from an exploratory
analysis of the CLARITY study evaluating the effect of Cladribine
Tablets on brain atrophy rates in patients with RRMS will be
presented. Additionally, final safety and tolerability results will
be presented from the phase II ONWARD study, which evaluated
Cladribine Tablets when added to interferon beta-1a therapy in
patients with active relapsing MS.

"Merck looks forward to sharing additional data with the
scientific community for Rebif® and Cladribine Tablets in MS," said
Luciano Rossetti, Global Head of Research & Development for Merck's
biopharma business. "The Company's scientific presence at this year's
congress, and the Rebif® and Cladribine Tablets data presented,
underscore our strong commitment to the MS community and to advancing
patient care."

The following seven abstracts have been accepted for presentation
at EAN (Central European Time):

Abstracts at a Glance

All posters will be available throughout the congress on the
poster screens and poster stations in the exhibition area.

Abstract 1178; May 29, 2016, 12:30-13:15

Adherence to Subcutaneous Interferon Beta-1a in Patients
Participating in the RebiSTAR® Patient Service Program: Interim
Analysis of the Non-Interventional Study RebiSTART; A. Chan